Company Monitoring Page for Bluebird-Bio

latest headlines for company on cafepharma

Gene therapy uptake in sickle cell stays slow, despite patient interest
BioPharma Dive
Mon, 12/9/24 - 10:37 am
Tags:
gene therapy, sickle cell disease, patients, Casgevy, Lyfgenia, Bluebird Bio, Vertex Pharmaceuticals
FDA considers 'regulatory action' for bluebird's Skysona after blood cancer reports
Fierce Pharma
Mon, 12/2/24 - 07:46 pm
Tags:
Bluebird Bio, Skysona, gene therapy, FDA, blood cancer, cALD
FDA probes blood cancer risk from bluebird's gene therapy, weighs regulatory action
Medpage Today
Wed, 11/27/24 - 09:59 pm
Tags:
Bluebird Bio, Skysona, FDA, myelodysplastic syndrome, AML, cALD
New data underline cancer risk of Bluebird therapy for brain disease
BioPharma Dive
Thu, 10/10/24 - 11:15 am
Tags:
Bluebird Bio, gene therapy, Skysona, cALD
Bluebird bio lays off 25% of workforce as gene therapy pioneer struggles to stay afloat
Fierce Pharma
Tue, 09/24/24 - 11:35 am
Tags:
Bluebird Bio, layoffs, gene therapy
Why some gene therapies face sluggish launches
Medical Marketing and Media
Mon, 09/16/24 - 10:21 pm
Tags:
gene therapy, Bluebird Bio, Lyfgenia, drug launches
Bluebird stock plummets 18% with slow uptake of sickle cell disease gene therapy Lyfgenia
Fierce Pharma
Wed, 08/14/24 - 10:31 pm
Tags:
Bluebird Bio, sickle cell disease, Vertex Pharmaceuticals, Lyfgenia, Casgevy
US government declines to clear Bluebird fertility support for Zynteglo patients
BioPharma Dive
Mon, 07/22/24 - 06:54 pm
Tags:
Bluebird Bio, Zynteglo, HHS, Fertility
Bluebird Boasts Nearly 140% Revenue Jump, Still Misses Target
BioSpace
Fri, 05/10/24 - 11:10 am
Tags:
Bluebird Bio, earnings, gene therapy
In gene therapy race, bluebird leads Vertex in activating treatment centers but trails in patient starts
Fierce Pharma
Thu, 05/9/24 - 07:17 pm
Tags:
gene therapy, Vertex Pharmaceuticals, Bluebird Bio
First Patient Begins Newly Approved Sickle Cell Gene Therapy
NY Times, NY
Mon, 05/6/24 - 11:40 am
Tags:
Bluebird Bio, gene therapy, sickle cell disease, patients, Lyfgenia
Bluebird Extends Cash Runway with $175M Financing to Support Gene Therapy Launch
BioSpace
Tue, 03/19/24 - 11:22 am
Tags:
Bluebird Bio, funding, sickle cell disease, Lyfgenia
Bluebird bio inks first Medicaid coverage agreement for sickle cell gene therapy, signing on with Michigan
Fierce Pharma
Mon, 03/11/24 - 11:33 am
Tags:
Bluebird Bio, Michigan, lovo-cel, Lyfgenia, Medicaid, sickle cell disease, gene therapy
Why Bluebird Bio Stock Dived Into the Red on Tuesday
Motley Fool
Tue, 03/5/24 - 10:18 pm
Tags:
Bluebird Bio
Sickle Cell Gene Therapies Seen as Cost Effective Below $2M Threshold: Study
BioSpace
Tue, 01/23/24 - 11:18 am
Tags:
gene therapy, sickle cell disease, drug pricing, Vertex Pharmaceuticals, Bluebird Bio
Bluebird bio's Lyfgenia launch progresses with 2nd major outcomes-based coverage deal
Fierce Pharma
Thu, 01/4/24 - 11:37 am
Tags:
Bluebird Bio, Lyfgenia, sickle cell disease, gene therapy
Bluebird Looks to Raise $250M After Lukewarm Reception of SCD Gene Therapy
BioSpace
Tue, 12/19/23 - 10:21 am
Tags:
Bluebird Bio, funding
Bluebird’s Newly Approved SCD Gene Therapy Faces Rough Road with Hefty Price Tag, Boxed Warning
BioSpace
Mon, 12/11/23 - 11:20 am
Tags:
Bluebird Bio, sickle cell disease, Lyfgenia, gene therapy, CRISPR
FDA approves bluebird's sickle cell disease gene therapy. Can Lyfgenia overcome CRISPR's halo?
Fierce Pharma
Sun, 12/10/23 - 11:15 pm
Tags:
Bluebird Bio, sickle cell disease, FDA, CRISPR, Lyfgenia
Bluebird won't play off Vertex in deciding price for its lovo-cel gene therapy, exec says
Fierce Pharma
Tue, 11/7/23 - 11:02 pm
Tags:
Bluebird Bio, Vertex Pharmaceuticals, exa-cel, lovo-cel, sickle cell disease, drug pricing

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.